MONDAY, July 26 (HealthDay News) -- Tribenzor, a three-in-one
drug to treat high blood pressure, has been approved by the U.S.
Food and Drug Administration.
Tribenzor combines amlodipine, marketed by Pfizer as Norvasc,
olmesartan medoxomil, marketed by Daiichi Sankyo as Benicar, and a
third drug, hydrochlorothiazide. The combination medication was
approved for people whose high blood pressure isn't well controlled
on other combinations of anti-hypertension drugs.
Daiichi Sankyo, based in Japan with U.S. headquarters in
Parsippany, N.J., produces the newly approved drug.
In a news release, the company said adverse reactions to
once-daily Tribenzor could include dizziness, swelling, headache,
fatigue, muscle spasms, nausea, diarrhea or infections of the
respiratory or urinary tracts.
To learn more about high blood pressure, visit the U.S.
National Heart Lung and Blood Institute.